1-8 of 8
Susan L. Kelley
Close
Sort by
Journal Articles

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Clinical Trials & Observations
Paul G. Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Jacob Laubach, Daniel Sullivan, Melissa Alsina, Robert Schlossman, Irene M. Ghobrial, Deborah Doss, Nora Loughney, Laura McBride, Elizabeth Bilotti, Palka Anand, Lisa Nardelli, Sandra Wear, Gail Larkins, Min Chen, Mohamad H. Zaki, Christian Jacques, Kenneth C. Anderson
Journal: Blood
Blood (2013) 121 (11): 1961–1967.
https://doi.org/10.1182/blood-2012-08-450742
Published: 2013
Journal Articles

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Clinical Trials & Observations
Andrzej J. Jakubowiak, Kent A. Griffith, Donna E. Reece, Craig C. Hofmeister, Sagar Lonial, Todd M. Zimmerman, Erica L. Campagnaro, Robert L. Schlossman, Jacob P. Laubach, Noopur S. Raje, Tara Anderson, Melissa A. Mietzel, Colleen K. Harvey, Sandra M. Wear, Jennifer C. Barrickman, Craig L. Tendler, Dixie-Lee Esseltine, Susan L. Kelley, Mark S. Kaminski, Kenneth C. Anderson, Paul G. Richardson
Journal: Blood
Blood (2011) 118 (3): 535–543.
https://doi.org/10.1182/blood-2011-02-334755
Published: 2011
Journal Articles

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial

Andrzej J Jakubowiak, MD, PhD, Donna E. Reece, MD, Craig C. Hofmeister, MD, Sagar Lonial, MD, Todd M Zimmerman, MD, Erica L. Campagnaro, MD, Robert L. Schlossman, MD, Jacob P. Laubach, MD, Noopur Raje, MD, Tara B. Anderson, Kent A. Griffith, Melissa A. Hill, Colleen K. Harvey, Sandra Wear, Jennifer Barrickman, Craig L. Tendler, MD, Dixie-Lee Esseltine, MD, Susan L. Kelley, MD, Mark S. Kaminski, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2010) 116 (21): 1937.
https://doi.org/10.1182/blood.V116.21.1937.1937
Published: 2010
Journal Articles

Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial

Andrzej J Jakubowiak, MD, PhD, Dominik Dytfeld, MD, PhD, Sundar Jagannath, MD, David H. Vesole, MD, PhD, Tara B. Anderson, Brian K. Nordgren, Daniel Lebovic, MD, Keith E. Stockerl-Goldstein, MD, Kent A. Griffith, Melissa A. Hill, Colleen K. Harvey, Akari M. Dollard, Robert Ott, Susan L. Kelley, MD, Jennifer Barrickman, Michael Kauffman, MD, PhD, Ravi Vij, MD
Journal: Blood
Blood (2010) 116 (21): 862.
https://doi.org/10.1182/blood.V116.21.862.862
Published: 2010
Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Paul G Richardson, MD, David Siegel, MD, PhD, Rachid Baz, MD, Susan L. Kelley, MD, Nikhil C. Munshi, MD, Daniel Sullivan, MD, Melissa Alsina, MD, Deborah Doss, RN, OCN, Laura McBride, Gail Larkins, RN, Maria Lizza, BS, Xin Yu, Mohamed Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 864.
https://doi.org/10.1182/blood.V116.21.864.864
Published: 2010
Journal Articles

The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.

Sandra Wear, RN, Paul G. Richardson, MD, Carolyn Revta, MPH, Ravi Vij, MBBS, MD, Mark Fiala, BS, CCRP, Sagar Lonial, MD, Dixil Francis, MPH, CCRC, David Samuel diCapua Siegel, MD, PhD, Alex Schramm, BA, Andrzej J. Jakubowiak, MD, PhD, Colleen K. Harvey, Donna E. Reece, MD, Engin Gul, HonBSc, Sundar Jagannath, MD, Lisa La, MS, Craig C. Hofmeister, MD, Buffy Jansak, BSN, OCN, Keith Stewart, MBA, MB, CHB, Rachel Hagerty, Jeffrey L. Wolf, MD, Beth Davis, Amrita Krishnan, MD, Lupe Duarte, CCRC, Todd M. Zimmerman, MD, Angela Cisneros, Shaji Kumar, MD, Ann Birgin, CRA, Robert Ott, MBA, Leah Tasca, Susan L. Kelley, MD, Kenneth C. Anderson, MD, Kathy Giusti, MBA
Journal: Blood
Blood (2010) 116 (21): 3803.
https://doi.org/10.1182/blood.V116.21.3803.3803
Published: 2010
Journal Articles

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.

Andrzej J. Jakubowiak, MD, PhD, Donna E. Reece, Craig C. Hofmeister, MD, Sagar Lonial, MD, Todd M. Zimmerman, MD, Erica L. Campagnaro, MD, Robert L. Schlossman, MD, Jacob Laubach, Noopur Raje, MD, Tara Anderson, PA, Kent Griffith, Melissa Hill, Colleen Harvey, Akari M. Dollard, Sandra Wear, Jennifer Barrickman, Craig Tendler, MD, Dixie-Lee Esseltine, MD, Susan L. Kelley, MD, Mark S. Kaminski, MD, Kenneth C. Anderson, Paul G. Richardson, MD
Journal: Blood
Blood (2009) 114 (22): 132.
https://doi.org/10.1182/blood.V114.22.132.132
Published: 2009
Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.

Paul Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Daniel Sullivan, Laura McBride, Deborah Doss, Gail Larkins, Christian Jacques, Arlene Donaldson, Kenneth C. Anderson
Journal: Blood
Blood (2009) 114 (22): 301.
https://doi.org/10.1182/blood.V114.22.301.301
Published: 2009